ATE447566T1 - Amorphe form eines zellzyklus inhibitors - Google Patents

Amorphe form eines zellzyklus inhibitors

Info

Publication number
ATE447566T1
ATE447566T1 AT01982358T AT01982358T ATE447566T1 AT E447566 T1 ATE447566 T1 AT E447566T1 AT 01982358 T AT01982358 T AT 01982358T AT 01982358 T AT01982358 T AT 01982358T AT E447566 T1 ATE447566 T1 AT E447566T1
Authority
AT
Austria
Prior art keywords
cell cycle
amorphous form
cycle inhibitor
inhibitor
amorphous
Prior art date
Application number
AT01982358T
Other languages
English (en)
Inventor
Antonio Albano
Wantanee Phuapradit
Harpreet Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE447566T1 publication Critical patent/ATE447566T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicinal Preparation (AREA)
AT01982358T 2000-10-03 2001-09-26 Amorphe form eines zellzyklus inhibitors ATE447566T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23756300P 2000-10-03 2000-10-03
PCT/EP2001/011119 WO2002028855A2 (en) 2000-10-03 2001-09-26 Amorphous form of cell cycle inhibitor

Publications (1)

Publication Number Publication Date
ATE447566T1 true ATE447566T1 (de) 2009-11-15

Family

ID=22894259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982358T ATE447566T1 (de) 2000-10-03 2001-09-26 Amorphe form eines zellzyklus inhibitors

Country Status (15)

Country Link
US (4) US6482847B2 (de)
EP (1) EP1366040B1 (de)
JP (3) JP2004510771A (de)
KR (1) KR100554933B1 (de)
CN (1) CN1250541C (de)
AR (1) AR035064A1 (de)
AT (1) ATE447566T1 (de)
AU (2) AU1396502A (de)
BR (1) BRPI0114156B8 (de)
CA (1) CA2423286C (de)
DE (1) DE60140382D1 (de)
ES (1) ES2334012T3 (de)
MX (1) MXPA03002858A (de)
WO (1) WO2002028855A2 (de)
ZA (1) ZA200301593B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
EP1469827B1 (de) * 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphe von natrium-4-(4-chlor-2-hydroxybenzoyl)aminobutanoat
WO2003087335A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
CA2702935A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US8268354B2 (en) * 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
ES2531040T3 (es) * 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3896075A1 (de) * 2015-12-18 2021-10-20 Galecto Biotech AB Polymorphe formen und verfahren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular
US6036736A (en) 1998-04-03 2000-03-14 Wells Manufacturing Company, Inc. Ventilating method and apparatus
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9803261D0 (sv) 1998-09-25 1998-09-25 Siemens Elema Ab Andningsapparat
KR20020003864A (ko) * 1999-03-03 2002-01-15 피터 지. 스트링거 에키노칸딘/탄수화물 착물
US6326501B1 (en) 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability

Also Published As

Publication number Publication date
EP1366040B1 (de) 2009-11-04
CN1468231A (zh) 2004-01-14
JP5341331B2 (ja) 2013-11-13
US20020061922A1 (en) 2002-05-23
JP2012136534A (ja) 2012-07-19
ES2334012T3 (es) 2010-03-04
US6492530B1 (en) 2002-12-10
MXPA03002858A (es) 2003-07-14
CA2423286A1 (en) 2002-04-11
JP2008056670A (ja) 2008-03-13
US6469180B1 (en) 2002-10-22
US20020173532A1 (en) 2002-11-21
BRPI0114156B8 (pt) 2021-05-25
DE60140382D1 (de) 2009-12-17
ZA200301593B (en) 2004-06-22
US6486329B1 (en) 2002-11-26
AU2002213965B2 (en) 2007-07-19
JP2004510771A (ja) 2004-04-08
WO2002028855A3 (en) 2003-09-12
BRPI0114156B1 (pt) 2018-09-11
US20020173533A1 (en) 2002-11-21
AR035064A1 (es) 2004-04-14
CA2423286C (en) 2008-10-28
EP1366040A2 (de) 2003-12-03
KR100554933B1 (ko) 2006-03-03
US20020173534A1 (en) 2002-11-21
CN1250541C (zh) 2006-04-12
AU1396502A (en) 2002-04-15
WO2002028855A2 (en) 2002-04-11
US6482847B2 (en) 2002-11-19
BR0114156A (pt) 2003-07-29
KR20030036872A (ko) 2003-05-09

Similar Documents

Publication Publication Date Title
DE60143822D1 (de) Verwendung eines MoO3-Korrosionsinhibitors
EP1510210A4 (de) Immunitätsbedingte proteinkinase-hemmer
CY2013045I1 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
CY2015053I1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
NO20030135L (no) Piperidinforbindelser for anvendelse som CCR-3-inhibitorer
IS7434A (is) N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma
ATE447566T1 (de) Amorphe form eines zellzyklus inhibitors
DE60320933D1 (de) Rho-kinase inhibitoren
ATE237329T1 (de) Metalloprotease inhibitoren
EE05430B1 (et) Imidasolo-5-l-2-anilino-primidiinid raku proliferatsiooni inhibitsiooni agensitena
CY2004011I1 (el) Aσυμμετρη συνθεση της πρεγαβαλινης
NO20024521D0 (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
DE60123294D1 (de) Diazepan Derivate als Faktor X Inhibitor
DE60008527D1 (de) Zellproliferation inhibitoren
DE60306478D1 (de) Bitfolgenfilter eines Zufallszahlengenerators
DE60218894D1 (de) Dreidimensionale profilierung eines heissschmelzhaftklebers zum erhalt von bereichen unterschiedlicher spannung
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
DE60136414D1 (de) Linearisierung eines Leistungsverstärkers
IS6507A (is) Píperidín- og píperasín útskipt N-hýdroxýformamíðsem málmpróteinasatálmar
NO20025786D0 (no) Protaseinhibitorer
EE200300116A (et) Efektiivne meetod faktori Xa inhibiitori valmistamiseks
NO20025605D0 (no) Nye MMP-2/MMP-9-inhibitorer
DE60116604D1 (de) Hintergrundkalibrierung eines a/d-umsetzers
NO20025005L (no) Proteaseinhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1366040

Country of ref document: EP